(Q45823728)

16 December 2017

title

Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012. (English)

1 reference

16 December 2017

0 references

1 reference

1

1 reference

16 December 2017

Marijke Reynders

object named as

M Reynders

6

0 references

Pierrette Melin

object named as

P Melin

5

0 references

author name string

C Rodeghiero

2

1 reference

16 December 2017

D Govaerts

3

1 reference

16 December 2017

I Leroux-Roels

4

1 reference

16 December 2017

S Van Der Meeren

7

1 reference

16 December 2017

S Van Den Wijngaert

8

1 reference

16 December 2017

D Pierard

9

1 reference

16 December 2017

publication date

27 September 2013

1 reference

16 December 2017

Epidemiology and Infection

published in

1 reference

16 December 2017

volume

142

1 reference

16 December 2017

issue

4

1 reference

16 December 2017

page(s)

724-728

1 reference

16 December 2017

Duration of immunity against pertussis after natural infection or vaccination

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Pertussis serodiagnosis in Belgium from 1990 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Rationale for pertussis booster vaccination throughout life in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Pertussis: increasing disease as a consequence of reducing transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

Maternal immunization: an update for pediatricians

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

7 January 2021

Vaccinate the village

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

7 January 2021

IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

7 January 2021

Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children

1 reference

https://api.crossref.org/works/10.1017%2FS0950268813002458

7 January 2021

10.1017/S0950268813002458

Identifiers

DOI

1 reference

16 December 2017

PubMed ID

24073712

1 reference

16 December 2017